Recombinant C. botulinum frr is expressed in heterologous systems such as E. coli, yeast, or mammalian cells . Key production steps include:
RRF collaborates with EF-G to disassemble post-termination ribosomal complexes into 30S and 50S subunits, enabling mRNA and tRNA release . Key findings include:
Helix H69 Displacement: RRF binding induces conformational changes in the 50S subunit’s H69 helix, destabilizing ribosomal integrity .
Species-Specific Activity: C. botulinum RRF functions optimally with homologous EF-G, but chimeric RRFs (e.g., E. coli Domain I + T. tengcongensis Domain II) exhibit reduced activity .
Recombinant frr is used as a subunit antigen in experimental vaccines targeting Clostridium pathogens. For example:
Neutralizing Antibodies: Mice immunized with recombinant C. botulinum Hc domains (a related antigen) developed protective antibodies against neurotoxins .
Adjuvant Compatibility: Alhydrogel® enhances frr immunogenicity, eliciting Th2-biased antibody responses .
Ribosome Dynamics: FRET-based assays and cryo-EM studies utilize recombinant frr to map ribosomal disassembly pathways .
Antibiotic Targets: RRF inhibitors are explored as novel antibiotics to disrupt bacterial protein synthesis .
KEGG: cbh:CLC_2279